116 related articles for article (PubMed ID: 36401730)
41. Long-term survivals of stage IIb osteosarcoma: a 20-year experience in a single institution.
Cho Y; Jung GH; Chung SH; Kim JY; Choi Y; Kim JD
Clin Orthop Surg; 2011 Mar; 3(1):48-54. PubMed ID: 21369478
[TBL] [Abstract][Full Text] [Related]
42. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy.
Hawkins DS; Arndt CA
Cancer; 2003 Dec; 98(11):2447-56. PubMed ID: 14635080
[TBL] [Abstract][Full Text] [Related]
43. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
[TBL] [Abstract][Full Text] [Related]
44. Limb-sparing in patients with non-metastatic high-grade osteosarcoma.
Samardziski M; Zafiroski G; Tolevska C; Zafirova-Ivanovska B; Kostadinova-Kunovska S; Kalicanin-Markovska M
J BUON; 2009; 14(1):63-9. PubMed ID: 19373949
[TBL] [Abstract][Full Text] [Related]
45. IAP Chemotherapy Regimen Is a Viable and Cost-effective Option in Children and Adolescents With Osteosarcoma: A Comparative Analysis With MAP Regimen on Toxicity and Survival.
Verma P; Jain S; Kapoor G; Tripathi R; Sharma P; Doval DC
J Pediatr Hematol Oncol; 2021 May; 43(4):e466-e471. PubMed ID: 32925402
[TBL] [Abstract][Full Text] [Related]
46. Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults.
Patel SJ; Lynch JW; Johnson T; Carroll RR; Schumacher C; Spanier S; Scarborough M
Am J Clin Oncol; 2002 Oct; 25(5):489-95. PubMed ID: 12393991
[TBL] [Abstract][Full Text] [Related]
47. Age and dose of chemotherapy as major prognostic factors in a trial of adjuvant therapy of osteosarcoma combining two alternating drug combinations and early prophylactic lung irradiation. French Bone Tumor Study Group.
Cancer; 1988 Apr; 61(7):1304-11. PubMed ID: 3125957
[TBL] [Abstract][Full Text] [Related]
48. [Effectiveness and safety of polyethylene glycol liposome doxorubicin in the treatment of osteosarcoma].
Yang YK; Xu HR; Huang Z; Li Y; Niu XH
Zhonghua Zhong Liu Za Zhi; 2020 Aug; 42(8):692-696. PubMed ID: 32867464
[No Abstract] [Full Text] [Related]
49. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup.
Souhami RL; Craft AW; Van der Eijken JW; Nooij M; Spooner D; Bramwell VH; Wierzbicki R; Malcolm AJ; Kirkpatrick A; Uscinska BM; Van Glabbeke M; Machin D
Lancet; 1997 Sep; 350(9082):911-7. PubMed ID: 9314869
[TBL] [Abstract][Full Text] [Related]
50. Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup.
McTiernan A; Jinks RC; Sydes MR; Uscinska B; Hook JM; van Glabbeke M; Bramwell V; Lewis IJ; Taminiau AH; Nooij MA; Hogendoorn PC; Gelderblom H; Whelan JS
Eur J Cancer; 2012 Mar; 48(5):703-12. PubMed ID: 22036088
[TBL] [Abstract][Full Text] [Related]
51. Secondary malignant neoplasms after osteosarcoma: early onset and cumulative alkylating agent dose dependency.
Kim SH; Shin KH; Seok SO; Cho YJ; Noh JK; Suh JS; Yang WI
Ann Surg Oncol; 2015 Mar; 22(3):859-65. PubMed ID: 25192682
[TBL] [Abstract][Full Text] [Related]
52. Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.
Gaspar N; Occean BV; Pacquement H; Bompas E; Bouvier C; Brisse HJ; Castex MP; Cheurfa N; Corradini N; Delaye J; Entz-Werlé N; Gentet JC; Italiano A; Lervat C; Marec-Berard P; Mascard E; Redini F; Saumet L; Schmitt C; Tabone MD; Verite-Goulard C; Le Deley MC; Piperno-Neumann S; Brugieres L; ; ;
Eur J Cancer; 2018 Jan; 88():57-66. PubMed ID: 29190507
[TBL] [Abstract][Full Text] [Related]
53. In vitro drug sensitivity (IDS) of patient-derived primary osteosarcoma cells as an early predictor of the clinical outcomes of osteosarcoma patients.
Klangjorhor J; Phanphaisarn A; Teeyakasem P; Chaiyawat P; Phinyo P; Settakorn J; Theera-Umpon N; Pruksakorn D
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1165-1176. PubMed ID: 32476109
[TBL] [Abstract][Full Text] [Related]
54. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651.
Goorin AM; Schwartzentruber DJ; Devidas M; Gebhardt MC; Ayala AG; Harris MB; Helman LJ; Grier HE; Link MP;
J Clin Oncol; 2003 Apr; 21(8):1574-80. PubMed ID: 12697883
[TBL] [Abstract][Full Text] [Related]
55. Neoadjuvant chemotherapy for osseous malignant fibrous histiocytoma of the extremity: results in 18 cases and comparison with 112 contemporary osteosarcoma patients treated with the same chemotherapy regimen.
Bacci G; Ferrari S; Bertoni F; Mercuri M; Forni C; Sottili S; Gasbarrini A; Tienghi A; Cesari M; Campanacci M
J Chemother; 1997 Aug; 9(4):293-9. PubMed ID: 9269611
[TBL] [Abstract][Full Text] [Related]
56. Radiotherapy and gemcitabine-docetaxel chemotherapy in children and adolescents with unresectable recurrent or refractory osteosarcoma.
Lee JA; Paik EK; Seo J; Kim DH; Lim JS; Yoo JY; Kim MS
Jpn J Clin Oncol; 2016 Feb; 46(2):138-43. PubMed ID: 26685322
[TBL] [Abstract][Full Text] [Related]
57. Analysis of bone and soft-tissue sarcomas registered during the year 2012 at Tata Memorial Hospital, Mumbai, with clinical outcomes.
Bajpai J; Khanna N; Vora T; Gulia A; Laskar S; Puri A; Sanduptla B; Chinnaswamy G; Nayak P; Juvekar SL; Janu A; Desai S; Ghosh J; Purandare N; Ramadwar M; Rangarajan V; Rekhi B
Indian J Cancer; 2018; 55(1):37-44. PubMed ID: 30147091
[TBL] [Abstract][Full Text] [Related]
58. Adjuvant chemotherapy for osteosarcoma may not increase survival after neoadjuvant chemotherapy and surgical resection.
Berend KR; Pietrobon R; Moore JO; Dibernardo L; Harrelson JM; Scully SP
J Surg Oncol; 2001 Nov; 78(3):162-70. PubMed ID: 11745799
[TBL] [Abstract][Full Text] [Related]
59. High-dose methotrexate and HELP [Holoxan (ifosfamide), eldesine (vindesine), platinum]--doxorubicin in non-metastatic osteosarcoma of the extremity: a French multicentre pilot study. Fédération Nationale des Centres de Lutte contre le Cancer and Société Française d'Oncologie Pédiatrique.
Philip T; Iliescu C; Demaille MC; Pacquement H; Gentet JC; Krakowski I; Soler-Michel P; Thiesse P; Chauvin F; Blay JY; Brunat-Mentigny M
Ann Oncol; 1999 Sep; 10(9):1065-71. PubMed ID: 10572604
[TBL] [Abstract][Full Text] [Related]
60. High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study.
Bacci G; Ferrari S; Longhi A; Picci P; Mercuri M; Alvegard TA; Saeter G; Donati D; Manfrini M; Lari S; Briccoli A; Forni C;
J Chemother; 2002 Apr; 14(2):198-206. PubMed ID: 12017378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
